Abdera Therapeutics to Present Key Updates on its Radiopharmaceutical Development Pipeline at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Dosing underway in Phase 1 clinical trial for ABD-147 (DLL3-targeting radiopharmaceutical) in patients with extensive stage small cell lung cancer and large cell neuroendocrine carcinoma of the lung; Abdera to present trial-in-progress posterPoster presentation of preclinical data for Abdera’s second development program, ABD-320, representing the first radiopharmaceutical therapy in development targeting 5T4
